Literature DB >> 31373033

C/EBPα mediates the growth inhibitory effect of progestins on breast cancer cells.

A Silvina Nacht1,2, Roberto Ferrari1,2, Roser Zaurin1,2, Valentina Scabia3, José Carbonell-Caballero1,2, Francois Le Dily1,2, Javier Quilez1,2, Alexandra Leopoldi1,2, Cathrin Brisken3, Miguel Beato1,2,4, Guillermo P Vicent1,2.   

Abstract

Steroid hormones are key gene regulators in breast cancer cells. While estrogens stimulate cell proliferation, progestins activate a single cell cycle followed by proliferation arrest. Here, we use biochemical and genome-wide approaches to show that progestins achieve this effect via a functional crosstalk with C/EBPα. Using ChIP-seq, we identify around 1,000 sites where C/EBPα binding precedes and helps binding of progesterone receptor (PR) in response to hormone. These regions exhibit epigenetic marks of active enhancers, and C/EBPα maintains an open chromatin conformation that facilitates loading of ligand-activated PR. Prior to hormone exposure, C/EBPα favors promoter-enhancer contacts that assure hormonal regulation of key genes involved in cell proliferation by facilitating binding of RAD21, YY1, and the Mediator complex. Knockdown of C/EBPα disrupts enhancer-promoter contacts and decreases the presence of these architectural proteins, highlighting its key role in 3D chromatin looping. Thus, C/EBPα fulfills a previously unknown function as a potential growth modulator in hormone-dependent breast cancer.
© 2019 The Authors.

Entities:  

Keywords:  C/EBPα; breast cancer; cell proliferation; hormone-dependent gene regulation; progesterone receptor

Mesh:

Substances:

Year:  2019        PMID: 31373033      PMCID: PMC6745496          DOI: 10.15252/embj.2018101426

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  86 in total

1.  The Pioneer Transcription Factor FoxA Maintains an Accessible Nucleosome Configuration at Enhancers for Tissue-Specific Gene Activation.

Authors:  Makiko Iwafuchi-Doi; Greg Donahue; Akshay Kakumanu; Jason A Watts; Shaun Mahony; B Franklin Pugh; Dolim Lee; Klaus H Kaestner; Kenneth S Zaret
Journal:  Mol Cell       Date:  2016-04-07       Impact factor: 17.970

2.  Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.

Authors:  Sigal Gery; Sakae Tanosaki; Shikha Bose; Namrata Bose; Jay Vadgama; H Phillip Koeffler
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

3.  Comprehensive genome-wide protein-DNA interactions detected at single-nucleotide resolution.

Authors:  Ho Sung Rhee; B Franklin Pugh
Journal:  Cell       Date:  2011-12-09       Impact factor: 41.582

4.  The proline-histidine-rich CDK2/CDK4 interaction region of C/EBPalpha is dispensable for C/EBPalpha-mediated growth regulation in vivo.

Authors:  Bo Torben Porse; Thomas Askov Pedersen; Marie Sigurd Hasemann; Mikkel Bruhn Schuster; Peggy Kirstetter; Tom Luedde; Inge Damgaard; Elke Kurz; Charlotte Karlskov Schjerling; Claus Nerlov
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

Review 5.  Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors.

Authors:  Peter F Johnson
Journal:  J Cell Sci       Date:  2005-06-15       Impact factor: 5.285

6.  Cyclin D3 maintains growth-inhibitory activity of C/EBPalpha by stabilizing C/EBPalpha-cdk2 and C/EBPalpha-Brm complexes.

Authors:  Guo-Li Wang; Xiurong Shi; Elizabeth Salisbury; Yuxiang Sun; Jeffrey H Albrecht; Roy G Smith; Nikolai A Timchenko
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

7.  Comprehensive mapping of long-range interactions reveals folding principles of the human genome.

Authors:  Erez Lieberman-Aiden; Nynke L van Berkum; Louise Williams; Maxim Imakaev; Tobias Ragoczy; Agnes Telling; Ido Amit; Bryan R Lajoie; Peter J Sabo; Michael O Dorschner; Richard Sandstrom; Bradley Bernstein; M A Bender; Mark Groudine; Andreas Gnirke; John Stamatoyannopoulos; Leonid A Mirny; Eric S Lander; Job Dekker
Journal:  Science       Date:  2009-10-09       Impact factor: 47.728

8.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

9.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

10.  Two chromatin remodeling activities cooperate during activation of hormone responsive promoters.

Authors:  Guillermo Pablo Vicent; Roser Zaurin; A Silvina Nacht; Ang Li; Jofre Font-Mateu; Francois Le Dily; Michiel Vermeulen; Matthias Mann; Miguel Beato
Journal:  PLoS Genet       Date:  2009-07-17       Impact factor: 5.917

View more
  8 in total

1.  Chromatin topology defines estradiol-primed progesterone receptor and PAX2 binding in endometrial cancer cells.

Authors:  Nicolás Bellora; François Le Dily; Alejandro La Greca; Rodrigo Jara; Ana Silvina Nacht; Javier Quilez Oliete; José Luis Villanueva; Enrique Vidal; Gabriela Merino; Cristóbal Fresno; Inti Tarifa Reischle; Griselda Vallejo; Guillermo Vicent; Elmer Fernández; Miguel Beato; Patricia Saragüeta
Journal:  Elife       Date:  2022-01-12       Impact factor: 8.140

2.  Functional mapping of androgen receptor enhancer activity.

Authors:  Chia-Chi Flora Huang; Shreyas Lingadahalli; Tunc Morova; Dogancan Ozturan; Eugene Hu; Ivan Pak Lok Yu; Simon Linder; Marlous Hoogstraat; Suzan Stelloo; Funda Sar; Henk van der Poel; Umut Berkay Altintas; Mohammadali Saffarzadeh; Stephane Le Bihan; Brian McConeghy; Bengul Gokbayrak; Felix Y Feng; Martin E Gleave; Andries M Bergman; Colin Collins; Faraz Hach; Wilbert Zwart; Eldon Emberly; Nathan A Lack
Journal:  Genome Biol       Date:  2021-05-11       Impact factor: 13.583

3.  ERα-36 regulates progesterone receptor activity in breast cancer.

Authors:  Henri-Philippe Konan; Loay Kassem; Soleilmane Omarjee; Ausra Surmieliova-Garnès; Julien Jacquemetton; Elodie Cascales; Amélie Rezza; Olivier Trédan; Isabelle Treilleux; Coralie Poulard; Muriel Le Romancer
Journal:  Breast Cancer Res       Date:  2020-05-19       Impact factor: 6.466

Review 4.  3D chromatin architecture and epigenetic regulation in cancer stem cells.

Authors:  Yuliang Feng; Xingguo Liu; Siim Pauklin
Journal:  Protein Cell       Date:  2021-01-16       Impact factor: 14.870

5.  A set of accessible enhancers enables the initial response of breast cancer cells to physiological progestin concentrations.

Authors:  Roser Zaurin; Roberto Ferrari; Ana Silvina Nacht; Jose Carbonell; Francois Le Dily; Jofre Font-Mateu; Lara Isabel de Llobet Cucalon; Enrique Vidal; Antonios Lioutas; Miguel Beato; Guillermo P Vicent
Journal:  Nucleic Acids Res       Date:  2021-12-16       Impact factor: 16.971

6.  C/EBPα mediates the growth inhibitory effect of progestins on breast cancer cells.

Authors:  A Silvina Nacht; Roberto Ferrari; Roser Zaurin; Valentina Scabia; José Carbonell-Caballero; Francois Le Dily; Javier Quilez; Alexandra Leopoldi; Cathrin Brisken; Miguel Beato; Guillermo P Vicent
Journal:  EMBO J       Date:  2019-08-02       Impact factor: 11.598

Review 7.  90 YEARS OF PROGESTERONE: Molecular mechanisms of progesterone receptor action on the breast cancer genome.

Authors:  Miguel Beato; Roni H G Wright; François Le Dily
Journal:  J Mol Endocrinol       Date:  2020-07       Impact factor: 5.098

Review 8.  The Importance of Breast Adipose Tissue in Breast Cancer.

Authors:  Charu Kothari; Caroline Diorio; Francine Durocher
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.